
AMT Medical
Developing minimally invasive technology for coronary artery bypass surgery.
Date | Investors | Amount | Round |
---|---|---|---|
investor investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor | €0.0 | round | |
investor | €0.0 | round | |
* | $25.0m | Series B | |
Total Funding | 000k |
Related Content
AMT Medical is a Dutch medtech company focused on revolutionizing coronary artery bypass grafting (CABG) through a minimally invasive approach. The company is developing a proprietary surgical technology called ELANA (Excimer Laser Assisted Non-Occlusive Anastomosis), designed to simplify and enhance the bypass procedure without the need for stopping the heart or using a heart-lung machine.
Traditional open-heart bypass surgery involves significant trauma, long recovery times, and substantial risk. AMT Medical’s ELANA technology enables off-pump, minimally invasive bypass surgery by allowing surgeons to create a connection between blood vessels using a laser and specialized connector—without clamping or interrupting blood flow. This method reduces the need for full sternotomy and can be performed through small incisions, resulting in shorter hospital stays, less pain, and faster recovery for patients.
AMT Medical collaborates closely with cardiac surgeons, researchers, and hospitals across Europe to validate and refine its technology through clinical studies. The company’s goal is to make minimally invasive CABG the new standard of care for patients with coronary artery disease, particularly those who are high-risk or not ideal candidates for traditional procedures.
Keywords: AMT Medical, ELANA, coronary artery bypass, CABG, minimally invasive surgery, cardiovascular innovation, off-pump heart surgery, medical devices, cardiac surgery, Dutch medtech, laser-assisted anastomosis, heart bypass technology, patient recovery, surgical innovation.